SkinHealth Systems Inc. (SKIN) SEC Filings & Earnings Calls
EquiReason read 20 SkinHealth Systems Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-14 — SkinHealth Systems announces a 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance; no operational or financial guidance change..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- —
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
14 Oct 20268-K · 3.03, 5.03, 7.01SkinHealth Systems announces a 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance; no operational or financial guidance change.open
Figures in the filing · each found in the filing text
| outstanding shares (pre-split) · 2026-10-07 | 130,300,000 | |
| outstanding shares (post-split) · 2026-10-14 | 6,500,000 |
Risks flagged
Reverse stock split may not achieve sustained bid price compliance; liquidity may decrease.
“the Reverse Stock Split may not result in a sustained increase in the per share trading price... may decrease the trading liquidity” · word for word
6 Oct 20268-K · 1.02, 7.01SkinHealth Systems Inc. repays remaining $103.235M of 1.25% Convertible Senior Notes due 2026 in full, satisfying and discharging the indenture.open
Figures in the filing · each found in the filing text
| Convertible Notes Principal Repaid · 2026-09-30 | $103M | |
| Accrued Interest Paid · 2026-09-30 | $645218.75 |
Risks flagged
Debt repayment reduces leverage but may indicate limited refinancing options or use of cash.
“Repayment of convertible notes due 2026; no new debt issuance disclosed.”
14 Aug 20268-K · 5.02Chief Operations, Quality and Technology Officer resigns to pursue other opportunities; no disagreement with company.open
Risks flagged
Operational leadership gap; potential disruption to operations.
“COO departure effective August 28, 2026.”
12 Aug 2026DEF 14AProxy statement seeking stockholder approval for a reverse stock split to regain Nasdaq compliance and avoid triggering convertible note repurchase obligations.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and restricted cash · 2026-06-30 | $206M |
Risks flagged
Nasdaq delisting risk
“On August 7, 2026, the closing price for our Class A Common Stock on the Nasdaq Capital Market was $0.6610 per share.” · word for word
Convertible note repurchase risk
“If a Fundamental Change were to occur while both series of Notes remain outstanding and holders exercised their repurchase rights in full, the approximately $353.2 million combined principal amount of the Notes would exceed our reported cash, cash equivalents and restricted cash as of June 30, 2026.”
6 Aug 20268-K · 2.02Q2 2026 net sales $72.1M (-7.8% YoY), delivery systems sold 770 (-19.5% YoY), net loss $(2.7)M vs net income $19.7M prior year; guidance cut for Q3 and FY2026 reflecting continued sales pressure.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $72M | -8% y/y |
| Delivery Systems net sales · Delivery Systems · Q2-2026 | $18M | -18% y/y |
| Consumables net sales · Consumables · Q2-2026 | $54M | -3% y/y |
| Gross margin · Q2-2026 | 68.4% | |
| Adjusted gross margin · Q2-2026 | 71.8% | |
| Adjusted EBITDA · Q2-2026 | $17M | +22% y/y |
| Adjusted EBITDA margin · Q2-2026 | 23.6% | |
| Total delivery systems sold · Q2-2026 | 770 | -20% y/y |
| Active install base · Q2-2026 | 36,516 | +4% y/y |
| Net (loss) income · Q2-2026 | $-3M | -114% y/y |
Guidance
Q3 2026 net sales $65-70M, adjusted EBITDA $5-7M; FY2026 net sales $280-290M, adjusted EBITDA $39-46M
Guidance cut reflecting continued sales pressure; Q3 net sales $65-70M, FY2026 $280-290M; adjusted EBITDA Q3 $5-7M, FY $39-46M
Risks flagged
Continued sales pressure across all regions, especially EMEA delivery systems down 38% YoY
“EMEA delivery systems sold 162 vs 261; net sales $14.9M vs $18.4M”
Transition to distributor model in Australia/New Zealand and China may disrupt revenue
“Company transitioned sales in Australia/New Zealand and China to distributor partners”
Debt maturity risk: 1.25% Convertible Senior Notes due October 2026
“Company's debt service obligations and the October 2026 maturity of its 1.25% Convertible Senior Notes” · word for word
Nasdaq minimum bid price deficiency and proposed reverse stock split
“continued listing on The Nasdaq Capital Market, including the minimum bid price deficiency and the proposed reverse stock split” · word for word
Securities class action settlement cash obligations
“proposed settlement of the Company's securities class action and related cash obligations” · word for word
6 Aug 202610-QQ2 2026 revenue declined 7.8% YoY with net loss of $2.7M, while gross margin improved to 68.4%.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $72M | -8% y/y |
| Gross margin · Q2-2026 | 68.4% | |
| Net loss · Q2-2026 | $-3M | |
| Cash and cash equivalents · 2026-06-30 | $206M | |
| Delivery Systems net sales · Delivery Systems · Q2-2026 | $18M | -18% y/y |
| Consumables net sales · Consumables · Q2-2026 | $54M | -4% y/y |
| Americas net sales · Americas · Q2-2026 | $50M | |
| EMEA net sales · EMEA · Q2-2026 | $15M | |
| Asia-Pacific net sales · Asia-Pacific · Q2-2026 | $7M |
Risks flagged
Nasdaq Delisting Risk
“On May 8, 2026, the Company received a notification letter...notifying the Company that the listing of its Class A common stock...was not in compliance with Nasdaq Listing Rule 5550(a)(2).” · word for word
Securities Class Action Settlement
“the Company will cause to be paid a total cash settlement payment of $18,000,000...the Company will be responsible to pay only $3,000,000 of the Cash Payment from its own funds” · word for word
SEC Investigation
“the SEC is conducting a formal investigation of the Company related to, among other things, the allegations brought against the Company in the Securities Class Action lawsuit.” · word for word
Debt Maturity Risk
“Current portion of convertible senior notes, net $103,089 as of June 30, 2026” · word for word
22 Jun 20268-K · 8.01Company enters $18M settlement of securities class action; $3M from company, $15M from insurers; subject to court approval.open
Figures in the filing · each found in the filing text
| Cash settlement payment | $18M | |
| Company's portion of settlement | $3M |
Risks flagged
Securities class action settlement requires $3M cash outlay, subject to court approval
“the Company will cause to be paid a total cash settlement payment of $18,000,000 (the “Cash Payment”), of which, the Company will be responsible to pay only $3,000,000 of the Cash Payment from its own funds” · word for word
12 May 20268-K · 3.01SkinHealth Systems received Nasdaq notice for non-compliance with minimum bid price rule ($1.00) for 30 consecutive days. 180-day cure period until Nov 4, 2026. Company intends to monitor and consider options, including reverse stock split.open
Risks flagged
Potential delisting from Nasdaq if bid price deficiency not cured within compliance period, which could severely impact liquidity and investor confidence.
“Nasdaq notice of non-compliance with Minimum Bid Price Requirement; if not cured, Common Stock subject to delisting.”
11 May 2026SC 13D/ALinden Capital Partners filed an administrative update to its Schedule 13D for SkinHealth Systems, reflecting a passive percentage change due to share count adjustment; no change in holdings or intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage (Linden Capital) · 2026-05-11 | 25.7% |
11 May 2026SC 13D/ALinden Capital Partners filed an administrative update to its Schedule 13D for SkinHealth Systems, reflecting a passive percentage change due to share count adjustment; no change in holdings or intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage (Linden Capital) · 2026-05-11 | 25.7% |
7 May 20268-K · 2.02Q1 2026 net sales $64.9M (-6.7% YoY), delivery systems sold 746 vs 862, net loss $(6.6)M, adjusted EBITDA $8.5M beat guidance. Full-year revenue guidance lowered to $280-295M from prior range.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $65M | -7% y/y |
| Gross margin · Q1-2026 | 68.5% | |
| Adjusted EBITDA · Q1-2026 | $9M | +16% y/y |
| Delivery systems sold · Q1-2026 | 746 | -13% y/y |
| Active install base · Q1-2026 | 36,419 | +4% y/y |
| Net loss · Q1-2026 | $-7M | -35% y/y |
Guidance
FY26 net sales $280-295M (prior not stated); Q2 net sales $72-77M; FY26 adjusted EBITDA $35-45M; Q2 adjusted EBITDA $11-13M
Full-year revenue guidance lowered reflecting continued pressure on device sales; adjusted EBITDA guidance maintained with margin improvement
Risks flagged
Revenue decline and lowered full-year guidance signal demand weakness
“Net sales decreased 6.7% YoY; full-year guidance cut to $280-295M”
Market conditions remain challenging with pressure on device sales
“While the market remains challenging and we are lowering our full-year revenue outlook” · word for word
7 May 202610-QQ1 2026 net sales declined 6.7% YoY, gross margin contracted 130bps, but operating loss narrowed significantly due to cost cuts.earningsopen
Figures in the filing · each found in the filing text
| Gross margin · Q1-2026 | 68.5% | |
| Loss from operations · Q1-2026 | $-2M | +85% y/y |
| Cash and cash equivalents · 2026-03-31 | $204M |
Risks flagged
Macroeconomic and credit headwinds
“Delivery Systems net sales were negatively impacted globally by unfavorable macroeconomic and credit conditions.” · word for word
China distributor transition risk
“Consumables net sales were negatively impacted by the transition to a distributor model in China, the timing of distributor orders, and promotions in the fourth quarter of 2025.” · word for word
Interest expense increase
“Interest expense for the three months ended March 31, 2026 increased $3.8 million compared to the three months ended March 31, 2025, primarily due to interest and amortization of debt issuance costs related to the 7.95% Convertible Senior Secured Notes due November 15, 2028” · word for word
6 May 20268-K · 5.02SkinHealth Systems Inc. terminated Chief Revenue Officer Ronald Menezes without cause, effective May 5, 2026. The termination was not due to any disagreement on financial reporting, operations, policies, or practices. A separation agreementopen
Risks flagged
Key executive departure could disrupt revenue operations and client relationships.
“Termination of Chief Revenue Officer without cause.”
24 Apr 2026DEF 14AProxy statement for 2026 annual meeting disclosing executive compensation, governance, and shareholder proposals.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $301M | |
| Adjusted EBITDA · FY2025 | $45M | |
| Net Income · FY2025 | $-10M | |
| Revenue · FY2025 | $301M | |
| Total Shareholder Return (TSR) · FY2025 | $10.82 | |
| Peer Group Total Shareholder Return · FY2025 | $142.22 | |
| Number of Employees · 2025-12-31 | 613 |
Risks flagged
Securities Class Action Lawsuit
“On November 16, 2023, a putative class action was filed ... asserting claims for violation of Section 10(b) of the Exchange Act ... The complaint alleged that, between May 10, 2022 and November 13, 2023, Defendants materially misled the investing public by publicly issuing false and/or misleading statements and/or omissions relating to Hydrafacial's business” · word for word
Customer Class Action Lawsuit
“On October 24, 2024, Jason Davalos ... filed a putative class action complaint ... against Hydrafacial and The Beauty Health Company ... for alleged violations of New York consumer fraud statutes, breach of contract, and common law breach of implied warranties ... The Complaint alleged that all three versions of the Syndeo machine (Syndeo 1.0, Syndeo 2.0, an”
SEC Investigation
“On January 11, 2024, the Company was informed that the SEC is conducting a formal investigation of the Company related to, among other things, the allegations brought against the Company in the Securities Class Action lawsuit.” · word for word
Consolidated Derivative Action
“On February 8, 2024, a derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Andrew Stanleick ... asserting a single claim for breach of fiduciary duty against the individual defendants based on the alleged disclosure of knowingly false information and/or the alleged failure to re” · word for word
Sientra Bankruptcy (Officer Background)
“On February 12, 2024, Sientra, along with its three affiliates, filed a voluntary petition under chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Prior to joining the Company, Mr. Menezes served as a director, President and Chief Executive Officer of Sientra from November 2020 through June 2024.” · word for word
12 Mar 202610-KAnnual report showing revenue decline but gross margin improvement.earningsopen
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $301M | -10% y/y |
| Gross margin · FY2025 | 65.3% | |
| Loss from operations · FY2025 | $-21M | |
| Cash and cash equivalents · FY2025 | $233M | -37% y/y |
Risks flagged
Debt refinancing risk
“Our business could also be adversely affected by our inability to repay or refinance existing debt. As of the filing date of this Annual Report on Form 10-K, we are in compliance with all of our debt covenants. However, we may be unable to satisfy financial covenants in the future, which could materially and adversely affect our ability to finance future ope” · word for word
Macroeconomic and credit conditions
“Delivery Systems net sales were negatively impacted globally by unfavorable macroeconomic and credit conditions.” · word for word
China market transition risk
“During the second quarter of 2025, the Company transitioned sales in the China market to a distributor partner, and as a result, the Company has discontinued direct sales to customers in China.” · word for word
Goodwill impairment risk
“If our goodwill or long-lived assets become impaired, we may be required to record a significant charge to earnings.” · word for word
12 Mar 20268-K · 2.02Q4 2025 net sales down 1.3% YoY to $82.4M, but gross margin improved to 64.4% from 62.7%, Adj. EBITDA up 67% to $15.0M. FY2025 net sales down 10% to $300.8M, Adj. EBITDA up 267% to $45.1M. Guidance for FY2026 net sales $285-305M, Adj. EBITDearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q4-2025 | $82M | -1% y/y |
| Net sales · FY2025 | $301M | -10% y/y |
| Gross margin · Q4-2025 | 64.4% | |
| Gross margin · FY2025 | 65.3% | |
| Adjusted EBITDA · Q4-2025 | $15M | +67% y/y |
| Adjusted EBITDA · FY2025 | $45M | +267% y/y |
| Delivery systems sold · Q4-2025 | 1,032 | -5% y/y |
| Delivery systems sold · FY2025 | 3,726 | -24% y/y |
| Active install base · FY2025 | 36,026 | +4% y/y |
| Net loss · Q4-2025 | $-8M | -21% y/y |
Guidance
Q1 2026 net sales $63-68M; Q1 2026 Adj. EBITDA $3.5-5.5M; FY2026 net sales $285-305M; FY2026 Adj. EBITDA $35-45M
Guidance implies stable to slightly lower revenue but continued margin improvement; management optimistic about commercial initiatives.
Risks flagged
Revenue decline continues, especially in delivery systems sales, indicating potential market saturation or competitive pressure.
“Net sales down 10% FY2025; delivery systems sold down 24%.”
Cash burn: cash balance decreased from $370M to $233M, partly due to debt repurchase, but still significant.
“Cash decreased by $137M in FY2025; $21.3M additional debt repurchase in Feb 2026.”
6 Nov 20258-K · 2.02Q3 2025 revenue $70.7M and Adj EBITDA $8.9M exceeded guidance; gross margin improved to 64.6% from 51.6% YoY; raised FY2025 guidance for net sales to $293-300M and Adj EBITDA to $37-39M.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $71M | -10% y/y |
| Gross margin · Q3-2025 | 64.6% | |
| Adjusted EBITDA · Q3-2025 | $9M | +10% y/y |
| Delivery systems sold · Q3-2025 | 875 | -22% y/y |
| Active install base · Q3-2025 | 35,409 | +4% y/y |
| Net loss · Q3-2025 | $-11M | -40% y/y |
| Cash, cash equivalents, and restricted cash · Q3-2025 | $219M | |
| Americas net sales · Americas · Q3-2025 | $48M | -7% y/y |
| APAC net sales · APAC · Q3-2025 | $6M | -42% y/y |
| EMEA net sales · EMEA · Q3-2025 | $16M | 0% y/y |
Guidance
FY2025 net sales $293-300M; Adjusted EBITDA $37-39M
FY2025 guidance raised for net sales and Adjusted EBITDA; reflects improvements in financial metrics.
Risks flagged
Device sales decline and macro headwinds persist; APAC weakness due to China distributor transition.
“Delivery systems sold down 21.7% YoY; APAC net sales down 41.7%.”
Cash burn from convertible note repurchase reduces liquidity buffer.
“Cash declined from $370M to $219M due to repurchase of convertible senior notes.”
6 Nov 202510-QQ3 2025 revenue declined 10.3% YoY with Delivery Systems down 24.6%, but gross margin improved to 64.6%.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $71M | -10% y/y |
| Gross margin · Q3-2025 | 64.6% | |
| Delivery Systems net sales · Delivery Systems · Q3-2025 | $21M | -25% y/y |
| Consumables net sales · Consumables · Q3-2025 | $50M | -3% y/y |
| Loss from operations · Q3-2025 | $-6M | |
| Cash, cash equivalents, and restricted cash · 2025-09-30 | $219M |
Risks flagged
Macroeconomic and credit headwinds
“Delivery Systems net sales were negatively impacted globally by unfavorable macroeconomic and credit conditions.” · word for word
China market transition disruption
“During the second quarter of 2025, the Company transitioned sales in the China market to a distributor partner, and as a result, the Company has discontinued direct sales to customers in China.” · word for word
Syndeo model issues
“Issues related to older models of Syndeo and our actions to remediate such issues.” · word for word
SkinHealth Systems Inc. — questions
- What did SkinHealth Systems Inc. file recently?
- 20 SEC filings in the last 12 months. Latest: 8-K on 2026-10-14 — SkinHealth Systems announces a 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance; no operational or financial guidance change.
Every figure on this page comes from SkinHealth Systems Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.